What does a CA‑125 level of 40 U/mL indicate and what are the appropriate next steps in evaluation?

CA-125 of 40 U/mL: Interpretation and Next Steps

A CA-125 level of 40 U/mL is mildly elevated and requires further evaluation with pelvic ultrasound (preferably transvaginal) performed by an expert examiner, as this level can indicate ovarian malignancy but is also commonly elevated in benign conditions.

Understanding the Result

Your CA-125 of 40 U/mL sits just above the traditional cutoff of 35 U/mL. However, this level is not specific to ovarian cancer and can be elevated in numerous benign conditions including endometriosis, ovarian cysts, menstruation, early pregnancy, and even non-gynecological conditions like heart failure 1.

Context Matters for Interpretation

The significance of this level depends heavily on your clinical context:

• Premenopausal women: CA-125 levels naturally fluctuate with the menstrual cycle, reaching up to 62 U/mL during menses and 51 U/mL during proliferative phase. A level of 40 U/mL may be physiologically normal depending on menstrual timing 2.

• Postmenopausal women: The upper limit should be lower—20 U/mL for those without vaginal bleeding and 35 U/mL for those with bleeding. A level of 40 U/mL in a postmenopausal woman warrants more aggressive investigation 2.

• Symptomatic patients: If you have symptoms like abdominal/pelvic pain, bloating, urinary frequency, or abdominal distension, this level becomes more concerning and requires prompt imaging 1.

Recommended Next Steps

Follow the ESMO 2023 guideline algorithm for suspected ovarian cancer 1:

1. Pelvic ultrasound by expert examiner (both transabdominal and transvaginal)

   • This is the most critical next step
   • US-based diagnostic models (IOTA Simple Rules or IOTA ADNEX) are superior to CA-125 alone for distinguishing benign from malignant ovarian tumors 1

2. Detailed clinical assessment

   • Document any symptoms: abdominal pain, bloating, changes in bowel/bladder habits, vaginal bleeding
   • Menstrual history and menopausal status
   • Family history of ovarian or breast cancer

3. If ultrasound shows suspicious findings:

   • CT scan of chest, abdomen, and pelvis for staging
   • Consider additional tumor markers (CEA and CA 19-9) if mucinous features are present to exclude gastrointestinal primary 1

4. If ultrasound is normal:

   • Repeat CA-125 in 3 months to assess trend
   • Rising levels (particularly doubling) are more concerning than a single mildly elevated value 3

Critical Pitfalls to Avoid

• Do not rely on CA-125 alone: Only 50% of early-stage ovarian cancers have elevated CA-125, and the marker lacks specificity 1

• Do not skip imaging: CA-125 of 40 U/mL has poor sensitivity and specificity as a standalone test. Ultrasound is essential 4

• Consider timing in premenopausal women: If you're menstruating, this level may be normal. Repeat testing in the luteal phase (when levels should be <32 U/mL) provides better discrimination 2

• Serial monitoring is more valuable than single values: A doubling of CA-125 or sustained increase over time is more predictive of malignancy than an isolated mildly elevated value 3

The Bottom Line

Proceed directly to expert pelvic ultrasound. The combination of imaging findings and CA-125 trends will guide whether you need CT staging, gynecologic oncology referral, or simply reassurance and monitoring. A single CA-125 of 40 U/mL cannot be interpreted in isolation—the clinical context, menopausal status, and imaging findings are essential for proper risk stratification 1, 2.